Search

Etodolac

Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

Enasidenib

Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) … This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation.

Ombitasvir

Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA Label]. … Ombutasvir is also available as a fixed-dose combination product with [DB09297] and [DB00503] as the FDA- and Health Canada-approved product Technivie.

Lorazepam

The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095] … [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977.

Benazepril

Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure . Upon cleavage of its ester group by the liver, benazepril is converted into its acti...

Cupric oxide

Cupric oxide, or copper (II) oxide, is an inorganic compound with the chemical formula CuO. … Cupric oxide poses potential health and environmental concern due to toxic and mutagenic particles generating reactive oxygen species [A32656].

Magnesium

[A32810] Despite the importance of magnesium and its availability via several food sources, an estimated 56 to 68% of adults who live in developed, western countries do not meet the recommended daily … Magnesium is classified as an alkaline earth metal and has 2 hydration shells.

Sodium borate

Thioproperazine

Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually ...

Certolizumab pegol

[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region.